Aligos Therapeutics (NASDAQ:ALGS) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aligos Therapeutics (NASDAQ:ALGS) released its quarterly earnings results on Thursday. The company reported ($2.21) EPS for the quarter, topping the consensus estimate of ($2.29) by $0.08, FiscalAI reports. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The business had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $0.25 million.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $6.03 on Friday. The firm has a market capitalization of $37.33 million, a price-to-earnings ratio of -0.70 and a beta of 2.28. Aligos Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $13.69. The stock’s fifty day moving average is $7.10 and its two-hundred day moving average is $8.16.

Institutional Trading of Aligos Therapeutics

Large investors have recently bought and sold shares of the company. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics in the third quarter valued at $99,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $106,000. DRW Securities LLC acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $111,000. XTX Topco Ltd acquired a new stake in Aligos Therapeutics in the second quarter valued at $100,000. Finally, Jane Street Group LLC acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $226,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALGS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Westpark Capital began coverage on Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.